Technology
Digital Genetic Twins Aim to Predict Disease but Face Legal and Ethical Hurdles
Synthesized from1 source
AI-generated summary
Digital Genetic Twins Aim to Predict Disease but Face Legal and Ethical Hurdles
Researchers and companies are developing AI-powered digital replicas of patients’ genomes to predict diseases and drug responses, while regulators and ethicists identify gaps in existing laws.
- Predictive AI’s “Doctor Twin AI” system predicts risks for over 22,000 conditions and responses to more than 210 drugs, the company stated.
- The “Evo 2” model, trained on 9 trillion DNA base pairs, identified disease-causing mutations in a breast cancer gene, as reported in Nature.
- A partnership between An Learn AI and Johnson & Johnson reduced control group size by up to one-third in Phase 3 Alzheimer’s trials, according to study results.
- A Harvard law school study concluded that current laws have structural problems for digital twins, including limited scope and conflicting intellectual property and accountability requirements.
TopicsHarvard Law SchoolIntellectual PropertyArtificial IntelligenceDrug ResponseBreast CancerEvo 2EthicsDigital TwinClinical trialsJohnson and JohnsonDisease PredictionGenome SequencingLegal RegulationAlzheimers Disease
Coverage
1 outlet — read the original reporting
Every story is brought together from multiple sources into a single, clear summary — with every perspective kept, not flattened.